Physician profile
Barbara Martin
NPI 1093754145
$1,871.04
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $111 · 2021: $206 · 2022: $464 · 2023: $478 · 2024: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $876.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $313.46 | 2021-2024 | Opzelura |
| Pfizer INC. | $246.97 | 2019-2024 | |
| Lilly USA, LLC | $241.77 | 2020-2024 | Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $208.92 | 2022-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $151.02 | 2023-2024 | |
| Amgen INC. | $144.96 | 2020-2024 | Otezla |
| Inspire Medical Systems, INC. | $126.02 | 2024 | Inspire |
| Leo Pharma INC. | $123.48 | 2019 | |
| Abbvie INC. | $85.98 | 2022-2024 | |
| Janssen Biotech, INC. | $70.13 | 2020-2022 | |
| Genzyme Corporation | $44.25 | 2023 | |
| Prugen, INC. Pharmaceuticals | $32.39 | 2019 | |
| Ucb, INC. | $20.48 | 2024 | Bimzelx |
| Sanofi-Aventis U.S. LLC | $19.47 | 2021 | |
| Allergan, INC. | $17.01 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $13.67 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.